![DexTech - Know-how in Translational Research](https://dextechmedical.com/wp-content/themes/dextech/img/bg/ref2.jpg)
DexTech is a Swedish research company specializing in drug development for urological oncology, primarily prostate cancer. Drug candidates are developed using CDC (carbohydrate-drug-conjugate) technology using a proprietary carbohydrate platform, GUA-Dex. The company conducts translational research and has a strong clinical foundation with specialist expertise in clinical oncology, pre-clinical research, and process development for drug manufacturing.